首页|Increased Incidence of Severe Adverse Events in Non-Small Cell Lung Cancer Patients with Previous Tuberculosis Episode Treated with PD-1 Inhibitors
Increased Incidence of Severe Adverse Events in Non-Small Cell Lung Cancer Patients with Previous Tuberculosis Episode Treated with PD-1 Inhibitors
扫码查看
点击上方二维码区域，可以放大扫码查看
原文链接
NETL
NSTL
万方数据
Lung cancer is the top cause of cancer deaths globally.Advances in immune checkpoint inhibitors(ICIs)have transformed cancer treatment,but their use in lung cancer has led to more side effects.This study examined if past pulmonary tuberculosis(TB)affects ICIs'effectiveness and safety in lung cancer treatment.We reviewed lung cancer patients treated with ICIs at Beijing Chest Hospital from January 2019 to August 2022.We compared outcomes and side effects between patients with and without prior TB.Of 116 patients(40 with TB history,76 without),prior TB didn't reduce treatment effectiveness but did increase severe side effects.Notably,older patients(≥65 years)faced a higher risk of severe side effects.Detailed cases of two patients with severe side effects underscored TB as a risk factor in lung cancer patients receiving ICIs,stressing the need for careful monitoring and personalized care.
Department of Medical Oncology,Beijing Chest Hospital,Capital Medical University&Beijing Tuberculosis and Thoracic Tumor Research Institute,Beijing 101149,China
Department of Bacteriology and Immunology,Beijing Key Laboratory on Drug-Resistant Tuberculosis Research,Beijing Chest Hospital,Capital Medical University/Beijing Tuberculosis&Thoracic Tumor Research Institute,Beijing 101149,China
Chinese Center for Disease Control and Prevention,Beijing 102206,China
Beijing Hospitals Authority Clinical Medicine Development of Special FundingBeijing Key Clinical Specialty ProjectTongzhou Lianggao Talents ProjectBeijing Nova Program
NETL
NSTL
万方数据
